Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F van de Werf

Showing results (11-20 of 290) with videos related to

Pageof 29
Sort By:
Haemostasis|March 1, 1994
Thrombolysis for acute myocardial infarctionF Van de Werf
Lancet (London, England)|June 17, 1989
Discrepancies between the effects of coronary reperfusion on survival and left ventricular functionF Van de Werf
European Heart Journal|June 12, 1999
Specific thrombin inhibitors ... only one tool of the antithrombotic armamentariumF Van De Werf
European Heart Journal|March 1, 1996
More evidence for a beneficial effect of platelet glycoprotein IIb/IIIa-blockade during coronary interventions. Latest results from the EPILOG and CAPTURE trialsF van de Werf
Circulation|August 15, 1996
International workshop on antithrombotic therapy for acute coronary syndromes. May 9-10, 1996, Como, ItalyF Van de Werf
Journal of the American College of Cardiology|December 1, 1988
Lessons from the European Cooperative recombinant tissue-type plasminogen activator (rt-PA) versus placebo trialF Van de Werf
American Heart Journal|August 2, 2001
New data in treatment of acute coronary syndromesF Van de Werf
American Heart Journal|July 30, 1999
What do new lytics add to t-PA?F Van de Werf
Zeitschrift Fur Kardiologie|January 1, 1993
Coronary patency after thrombolysisF Van de Werf
European Heart Journal|January 1, 1996
Selecting the most appropriate reperfusion therapy for acute myocardial infarction. How useful are guidelines?F van de Werf
Pageof 29

Showing results (11-20 of 290) with videos related to

Sort By:
Pageof 29
Haemostasis|March 1, 1994
Thrombolysis for acute myocardial infarctionF Van de Werf
Lancet (London, England)|June 17, 1989
Discrepancies between the effects of coronary reperfusion on survival and left ventricular functionF Van de Werf
European Heart Journal|June 12, 1999
Specific thrombin inhibitors ... only one tool of the antithrombotic armamentariumF Van De Werf
European Heart Journal|March 1, 1996
More evidence for a beneficial effect of platelet glycoprotein IIb/IIIa-blockade during coronary interventions. Latest results from the EPILOG and CAPTURE trialsF van de Werf
Circulation|August 15, 1996
International workshop on antithrombotic therapy for acute coronary syndromes. May 9-10, 1996, Como, ItalyF Van de Werf
Journal of the American College of Cardiology|December 1, 1988
Lessons from the European Cooperative recombinant tissue-type plasminogen activator (rt-PA) versus placebo trialF Van de Werf
American Heart Journal|August 2, 2001
New data in treatment of acute coronary syndromesF Van de Werf
American Heart Journal|July 30, 1999
What do new lytics add to t-PA?F Van de Werf
Zeitschrift Fur Kardiologie|January 1, 1993
Coronary patency after thrombolysisF Van de Werf
European Heart Journal|January 1, 1996
Selecting the most appropriate reperfusion therapy for acute myocardial infarction. How useful are guidelines?F van de Werf
Pageof 29